These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8390560)

  • 21. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C.
    Orito E; Mizokami M; Suzuki K; Ohba K; Ohno T; Mori M; Hayashi K; Kato K; Iino S; Lau JY
    J Med Virol; 1995 Jun; 46(2):109-15. PubMed ID: 7636496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
    Suzuki T; Tanaka E; Matsumoto A; Urushihara A; Sodeyama T
    J Med Virol; 1995 Jun; 46(2):162-8. PubMed ID: 7636506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha.
    Kanto T; Hayashi N; Takehara T; Hagiwara H; Mita E; Oshita M; Katayama K; Kasahara A; Fusamoto H; Kamada T
    J Med Virol; 1995 Jul; 46(3):230-7. PubMed ID: 7561795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA.
    Yokosuka O; Kato N; Hosoda K; Ito Y; Imazeki F; Ohto M; Omata M
    Gut; 1995 Nov; 37(5):721-6. PubMed ID: 8549952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study.
    Vogel W; Graziadei I; Umlauft F; Datz C; Hackl F; Allinger S; Grünewald K; Patsch J
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):81S-85S. PubMed ID: 9011481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
    Reichard O; Foberg U; Frydén A; Mattsson L; Norkrans G; Sönnerborg A; Wejstål R; Yun ZB; Weiland O
    Hepatology; 1994 Feb; 19(2):280-5. PubMed ID: 7507462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison.
    Tong MJ; Blatt LM; McHutchison JG; Co RL; Conrad A
    Hepatology; 1997 Dec; 26(6):1640-5. PubMed ID: 9398010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant interferon-alfa therapy in children with chronic hepatitis C.
    Bortolotti F; Giacchino R; Vajro P; Barbera C; Crivellaro C; Alberti A; Nebbia G; Zancan L; De Moliner L; Bertolini A
    Hepatology; 1995 Dec; 22(6):1623-7. PubMed ID: 7489965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction.
    Sugano M; Hayashi Y; Yoon S; Kinoshita M; Ninomiya T; Ohta K; Itoh H; Kasuga M
    J Clin Pathol; 1995 Sep; 48(9):820-5. PubMed ID: 7490314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.
    Martinot M; Marcellin P; Boyer N; Detmer J; Pouteau M; Castelnau C; Degott C; Aupérin A; Collins M; Kolberg J; Wilber J; Benhamou JP; Erlinger S
    Ann Intern Med; 1997 Jun; 126(11):874-81. PubMed ID: 9163288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
    Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
    Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of interferon-alpha on serum hepatitis C virus in patients with chronic hepatitis C.
    Shibata M; Kumada T; Yamada M; Nakano S; Kudo T; Morishima T
    Dig Dis Sci; 1993 Apr; 38(4):608-11. PubMed ID: 8384979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.
    Orito E; Mizokami M; Nakano T; Terashima H; Nojiri O; Sakakibara K; Mizuno M; Ogino M; Nakamura M; Matsumoto Y
    J Med Virol; 1994 Dec; 44(4):410-4. PubMed ID: 7897373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of early measurement of serum hepatitis C virus RNA in predicting response to interferon therapy in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Miyata A
    Eur J Gastroenterol Hepatol; 1997 Mar; 9(3):245-9. PubMed ID: 9096424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of quantitative cDNA-PCR with the branched DNA hybridization assay for monitoring plasma hepatitis C virus RNA levels in haemophilia patients participating in a controlled interferon trial.
    Bresters D; Cuypers HT; Reesink HW; Mauser-Bunschoten EP; van den Berg HM; Schaasberg WP; Wilber JC; Urdea MS; Neuwald P; Lelie PN
    J Med Virol; 1994 Jul; 43(3):262-8. PubMed ID: 7931188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mooren-type hepatitis C virus-associated corneal ulceration.
    Wilson SE; Lee WM; Murakami C; Weng J; Moninger GA
    Ophthalmology; 1994 Apr; 101(4):736-45. PubMed ID: 7512254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy.
    Hino K; Okuda M; Konishi T; Ishiko H; Okita K
    Dig Dis Sci; 1995 Jan; 40(1):14-20. PubMed ID: 7821101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.